<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39395130</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2509-2723</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>12</Day></PubDate></JournalIssue><Title>GeroScience</Title><ISOAbbreviation>Geroscience</ISOAbbreviation></Journal><ArticleTitle>Broad immunogenicity to prior SARS-CoV-2 strains and JN.1 variant elicited by XBB.1.5 vaccination in nursing home residents.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1007/s11357-024-01346-2</ELocationID><Abstract><AbstractText>SARS-CoV-2 vaccination has reduced hospitalization and mortality for nursing home residents (NHRs) but emerging variants and waning immunity challenge vaccine effectiveness. This study assesses the immunogenicity of the most recent XBB.1.5 monovalent vaccine to variant strains among NHRs. Participants were subset of a longitudinal study of consented NHRs and Healthcare workers (HCWs) who have received serial blood draws to assess immunogenicity with each SARS-CoV-2 mRNA vaccine dose. We report data on participants who received the XBB.1.5 monovalent vaccine post-FDA approval in Fall 2023. NHRs were categorized by whether they had an interval SARS-CoV-2 infection between their first bivalent vaccine dose and their XBB.1.5 monovalent vaccination. The sample included 61 NHRs [median age 76 (IQR 68-86), 51% female] and 28 HCWs [median age 45 (IQR 31-58), 46% female). After XBB.1.5 vaccination, a robust geometric mean fold rise (GMFR) in XBB.1.5-specific neutralizing antibody titers was observed:17.3 (95% confidence interval [CI] 9.3, 32.4) and NHRs with interval infection and 11.3 (95% CI 5, 25.4) in those without and 13.6 (95% CI 8.4,22) in HCWs. For JN.1-specific titers, GMFRs were 14.9 (95% CI 7.9, 28) and 6.5 (95% CI 3.3, 13.1) in NHRs with and without interval infection, and 11.4 (95% CI 6.2, 20.9) in HCWs. NHRs with interval SARS-CoV-2 infection had higher titers across all analyzed strains analyzed. The XBB.1.5 vaccine significantly elevates Omicron-specific neutralizing antibody titers to XBB.1.5 and JN.1 strains in both NHRs and HCWs with more pronounced in those previously infected with SARS-CoV-2 since bivalent vaccination.</AbstractText><CopyrightInformation>© 2024. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Abul</LastName><ForeName>Yasin</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0001-7062-6920</Identifier><AffiliationInfo><Affiliation>Center On Innovation in Long-Term Services &amp; Supports, Providence Veterans Administration Medical Center, Providence, RI, USA. yasin_abul@brown.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Geriatrics and Palliative Medicine, Warren Alpert Medical School of Brown University, Providence, RI, USA. yasin_abul@brown.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Case Western Reserve University School of Medicine, Cleveland, OH, USA. yasin_abul@brown.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Brown University School of Public Health, Providence, RI, USA. yasin_abul@brown.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nugent</LastName><ForeName>Clare</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Geriatrics and Palliative Medicine, Rhode Island Hospital, Providence, RI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vishnepolskiy</LastName><ForeName>Igor</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Center On Innovation in Long-Term Services &amp; Supports, Providence Veterans Administration Medical Center, Providence, RI, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Geriatrics and Palliative Medicine, Warren Alpert Medical School of Brown University, Providence, RI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wallace</LastName><ForeName>Tiffany</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Geriatrics and Palliative Medicine, Rhode Island Hospital, Providence, RI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dickerson</LastName><ForeName>Evan</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Division of Geriatrics and Palliative Medicine, Rhode Island Hospital, Providence, RI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holland</LastName><ForeName>Laurel</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of Geriatrics and Palliative Medicine, Rhode Island Hospital, Providence, RI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Esparza</LastName><ForeName>Iva</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Division of Geriatrics and Palliative Medicine, Warren Alpert Medical School of Brown University, Providence, RI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Winkis</LastName><ForeName>Mandi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Geriatrics and Palliative Medicine, Rhode Island Hospital, Providence, RI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wali</LastName><ForeName>Kazi Tanvee</ForeName><Initials>KT</Initials><AffiliationInfo><Affiliation>Division of Geriatrics and Palliative Medicine, Rhode Island Hospital, Providence, RI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>Philip A</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Warren Alpert Medical School of Brown University, Providence, RI, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Brown University School of Public Health, Providence, RI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baier</LastName><ForeName>Rosa R</ForeName><Initials>RR</Initials><AffiliationInfo><Affiliation>Brown University School of Public Health, Providence, RI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Recker</LastName><ForeName>Amy</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Brown University School of Public Health, Providence, RI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaczynski</LastName><ForeName>Matthew</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Geriatrics and Palliative Medicine, Warren Alpert Medical School of Brown University, Providence, RI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kamojjala</LastName><ForeName>Shreya</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Geriatrics and Palliative Medicine, Warren Alpert Medical School of Brown University, Providence, RI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pralea</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Geriatrics and Palliative Medicine, Warren Alpert Medical School of Brown University, Providence, RI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rice</LastName><ForeName>Hailee</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Division of Geriatrics and Palliative Medicine, Rhode Island Hospital, Providence, RI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Osias</LastName><ForeName>Olubunmi</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Division of Geriatrics and Palliative Medicine, Warren Alpert Medical School of Brown University, Providence, RI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oyebanji</LastName><ForeName>Oladayo A</ForeName><Initials>OA</Initials><AffiliationInfo><Affiliation>Case Western Reserve University School of Medicine, Cleveland, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Olagunju</LastName><ForeName>Olajide</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Case Western Reserve University School of Medicine, Cleveland, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Yi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Chia Jung</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roederer</LastName><ForeName>Alex</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pfeifer</LastName><ForeName>Walther M</ForeName><Initials>WM</Initials><AffiliationInfo><Affiliation>East Side Clinical Laboratory, East Providence, RI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bosch</LastName><ForeName>Jürgen</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Case Western Reserve University School of Medicine, Cleveland, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>King</LastName><ForeName>Christopher L</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>Case Western Reserve University School of Medicine, Cleveland, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nanda</LastName><ForeName>Aman</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Geriatrics and Palliative Medicine, Warren Alpert Medical School of Brown University, Providence, RI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McNicoll</LastName><ForeName>Lynn</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of Geriatrics and Palliative Medicine, Warren Alpert Medical School of Brown University, Providence, RI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mujahid</LastName><ForeName>Nadia</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Division of Geriatrics and Palliative Medicine, Warren Alpert Medical School of Brown University, Providence, RI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raza</LastName><ForeName>Sakeena</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Geriatrics and Palliative Medicine, Warren Alpert Medical School of Brown University, Providence, RI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tyagi</LastName><ForeName>Rohit</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Division of Geriatrics and Palliative Medicine, Warren Alpert Medical School of Brown University, Providence, RI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilson</LastName><ForeName>Brigid M</ForeName><Initials>BM</Initials><AffiliationInfo><Affiliation>Case Western Reserve University School of Medicine, Cleveland, OH, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Geriatric Research, Education and Clinical Center, VA Northeast Ohio Healthcare System, Cleveland, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>White</LastName><ForeName>Elizabeth M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Brown University School of Public Health, Providence, RI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Canaday</LastName><ForeName>David H</ForeName><Initials>DH</Initials><AffiliationInfo><Affiliation>Case Western Reserve University School of Medicine, Cleveland, OH, USA. dxc44@case.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Geriatric Research, Education and Clinical Center, VA Northeast Ohio Healthcare System, Cleveland, VA, USA. dxc44@case.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Gravenstein</LastName><ForeName>Stefan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Center On Innovation in Long-Term Services &amp; Supports, Providence Veterans Administration Medical Center, Providence, RI, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Geriatrics and Palliative Medicine, Warren Alpert Medical School of Brown University, Providence, RI, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Brown University School of Public Health, Providence, RI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Balazs</LastName><ForeName>Alejandro B</ForeName><Initials>AB</Initials><AffiliationInfo><Affiliation>Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>200-2016-91773</GrantID><Acronym>DP</Acronym><Agency>NCCDPHP CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AI129709-03S1</GrantID><Agency>Foundation for the National Institutes of Health</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Geroscience</MedlineTA><NlmUniqueID>101686284</NlmUniqueID><ISSNLinking>2509-2723</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="UpdateOf"><RefSource>medRxiv. 2024 Mar 29:2024.03.21.24303684. doi: 10.1101/2024.03.21.24303684</RefSource><PMID Version="1">38585784</PMID></CommentsCorrections></CommentsCorrectionsList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">JN.1 variant</Keyword><Keyword MajorTopicYN="N">Nursing homes</Keyword><Keyword MajorTopicYN="N">Older adults</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">XBB.1.5 monovalent vaccine</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>12</Day><Hour>21</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>12</Day><Hour>21</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>12</Day><Hour>11</Hour><Minute>8</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39395130</ArticleId><ArticleId IdType="doi">10.1007/s11357-024-01346-2</ArticleId><ArticleId IdType="pii">10.1007/s11357-024-01346-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Xie Y, Choi T, Al-Aly Z. Long-term outcomes following hospital admission for COVID-19 versus seasonal influenza: a cohort study. Lancet Infect Dis. 2023;24(3):239–55. https://doi.org/10.1016/S1473-3099(23)00684-9 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00684-9</ArticleId><ArticleId IdType="pubmed">38104583</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Medicare&amp;Medicaid Services. COVID-19 nursing home data. Available at: https://data.cms.gov/covid-19/covid-19-nursing-home-data . Accessed 1 Jul 2024.</Citation></Reference><Reference><Citation>CDC: risk assessment summary for SARS CoV-2 Sublineage BA.2.86. Available at https://www.cdc.gov/respiratory-viruses/whats-new/covid-19-variant.html . Accessed 2 Feb 2024.</Citation></Reference><Reference><Citation>Update on SARS-CoV-2 variant JN.1 being tracked by CDC. Available at https://www.cdc.gov/respiratory-viruses/whats-new/SARS-CoV-2-variant-JN.1.html . Accessed 26 Jun 2024.</Citation></Reference><Reference><Citation>Kaku Y, Okumura K, Padilla-Blanco M, et al. Virological characteristics of the SARS-CoV-2 JN.1 variant. Lancet Infect Dis. 2024;24:e82.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00813-7</ArticleId><ArticleId IdType="pubmed">38184005</ArticleId></ArticleIdList></Reference><Reference><Citation>Planas D, Staropoli I, Michel V, Lemoine F, et al. Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 lineages combining increased fitness and antibody evasion. Nat Commun. 2024;15(1):2254. https://doi.org/10.1038/s41467-024-46490-7 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-024-46490-7</ArticleId><ArticleId IdType="pubmed">38480689</ArticleId><ArticleId IdType="pmc">10938001</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID Data Tracker Variant Proportions. Available at https://covid.cdc.gov/covid-data-tracker/#variant-proportions .</Citation></Reference><Reference><Citation>Canaday DH, Oyebanji OA, White E, et al. COVID-19 vaccine booster dose needed to achieve Omicron-specific neutralisation in nursing home residents. EbioMed. 2022;80:104066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2022.104066</ArticleId></ArticleIdList></Reference><Reference><Citation>Nugent C, Abul Y, White EM, et al. Second monovalent SARS-CoV-2 mRNA booster restores Omicron-specific neutralizing activity in both nursing home residents and health care workers. Vaccine. 2023;41:3403–9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2023.04.034</ArticleId><ArticleId IdType="pubmed">37117056</ArticleId><ArticleId IdType="pmc">10123357</ArticleId></ArticleIdList></Reference><Reference><Citation>Oyebanji OA, Abul Y, Wilson BM, et al. Neutralization and binding antibody response to second bivalent COVID-19 vaccination in nursing home residents. J Am Geriatr Soc. 2023;71:3947–50.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jgs.18557</ArticleId><ArticleId IdType="pubmed">37589423</ArticleId></ArticleIdList></Reference><Reference><Citation>CDC COVID Data Tracker: https://covid.cdc.gov/covid-data-tracker/#datatracker-home . Accessed 3 Jan 2023</Citation></Reference><Reference><Citation>Gravenstein S, DeVone F, Oyebanji OA, et al. Durability of immunity and clinical protection in nursing home residents following bivalent SARS-CoV-2 vaccination. MedRxiv Prepr Serv Health Sci. 2023;4:e239.</Citation></Reference><Reference><Citation>Chalkias S, McGhee N, Whatley JL, et al. Safety and immunogenicity of XBB.1.5-containing mRNA vaccines infectious diseases (except HIV/AIDS), 2023. Available at http://medrxiv.org/lookup/doi/ https://doi.org/10.1101/2023.08.22.23293434 .</Citation></Reference><Reference><Citation>Stankov MV, Hoffmann M, Gutierrez Jauregui R, et al. Humoral and cellular immune responses following BNT162b2 XBB.1.5 vaccination. Lancet Infect Dis. 2024;24:e1–3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00690-4</ArticleId><ArticleId IdType="pubmed">37995739</ArticleId></ArticleIdList></Reference><Reference><Citation>Marking U, Bladh O, Aguilera K, et al. Humoral immune responses to the monovalent XBB.1.5-adapted BNT162b2 mRNA booster in Sweden. Lancet Infect Dis. 2024;24(2):e80–1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00779-X</ArticleId><ArticleId IdType="pubmed">38190833</ArticleId></ArticleIdList></Reference><Reference><Citation>Canaday DH, Oyebanji OA, White EM, et al. SARS-CoV-2 antibody responses to the ancestral SARS-CoV-2 strain and Omicron BA.1 and BA.4/BA.5 variants in nursing home residents after receipt of bivalent COVID-19 vaccine - Ohio and Rhode Island, September-November 2022. MMWR Morb Mortal Wkly Rep. 2023;72:100–6.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7204a4</ArticleId><ArticleId IdType="pubmed">36701254</ArticleId><ArticleId IdType="pmc">9925133</ArticleId></ArticleIdList></Reference><Reference><Citation>Link-Gelles R, Ciesla AA, Mak J, et al. Early estimates of updated 2023-2024 (Monovalent XBB.1.5) COVID-19 vaccine effectiveness against symptomatic SARS-CoV-2 infection attributable to Co-circulating Omicron variants among immunocompetent adults - increasing community access to testing program, United States, September 2023-January 2024. MMWR Morb Mortal Wkly Rep. 2024;73:77–83.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7304a2</ArticleId><ArticleId IdType="pubmed">38300853</ArticleId><ArticleId IdType="pmc">10843065</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin D-Y, Xu Y, Gu Y, et al. Durability of bivalent boosters against Omicron subvariants. N Engl J Med. 2023;388:1818–20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2302462</ArticleId><ArticleId IdType="pubmed">37043647</ArticleId></ArticleIdList></Reference><Reference><Citation>Collier A-RY, Brown CM, McMahan KA, et al. Characterization of immune responses in fully vaccinated individuals after breakthrough infection with the SARS-CoV-2 delta variant. Sci Transl Med. 2022;14:eabn6150.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abn6150</ArticleId><ArticleId IdType="pubmed">35258323</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldberg Y, Mandel M, Bar-On YM, et al. Protection and waning of natural and hybrid immunity to SARS-CoV-2. N Engl J Med. 2022;386:2201–12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2118946</ArticleId><ArticleId IdType="pubmed">35613036</ArticleId></ArticleIdList></Reference><Reference><Citation>Altarawneh HN, Chemaitelly H, Ayoub HH, et al. Effects of previous infection, vaccination, and hybrid immunity against symptomatic Alpha, Beta, and Delta SARS-CoV-2 infections: an observational study. EBioMed. 2023;95:104734.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2023.104734</ArticleId></ArticleIdList></Reference><Reference><Citation>Altarawneh HN, Chemaitelly H, Ayoub HH, et al. Protective effect of previous SARS-CoV-2 infection against Omicron BA.4 and BA.5 subvariants. N Engl J Med. 2022;387:1620–2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2209306</ArticleId><ArticleId IdType="pubmed">36198139</ArticleId></ArticleIdList></Reference><Reference><Citation>Lasrado N, Barouch DH. SARS-CoV-2 hybrid immunity: the best of both worlds. J Infect Dis. 2023;228:1311–3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiad353</ArticleId><ArticleId IdType="pubmed">37592872</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaplonek P, Deng Y, Shih-Lu Lee J, et al. Hybrid immunity expands the functional humoral footprint of both mRNA and vector-based SARS-CoV-2 vaccines. Cell Rep Med. 2023;4(5):101048. https://doi.org/10.1016/j.xcrm.2023.101048 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2023.101048</ArticleId><ArticleId IdType="pubmed">37182520</ArticleId><ArticleId IdType="pmc">10126214</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JH, Sergi C, Kast RE, et al. Basic implications on three pathways associated with SARS-CoV-2. Biomed J. 2024;12:100766. https://doi.org/10.1016/j.bj.2024.100766 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bj.2024.100766</ArticleId></ArticleIdList></Reference><Reference><Citation>Jong hoon Lee, Consolato Sergi, Richard E. Kast et al. The picture theory of seven pathways associated with COVID-19 in the real world. 2024; PREPRINT (Version 2) available at Research Square https://doi.org/10.21203/rs.3.rs-3849399/v2</Citation></Reference><Reference><Citation>Gilbert PB, Montefiori DC, McDermott AB, et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science. 2022;375:43–50.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abm3425</ArticleId><ArticleId IdType="pubmed">34812653</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng S, Phillips DJ, White T, et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nat Med. 2021;27:2032–40.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01540-1</ArticleId><ArticleId IdType="pubmed">34588689</ArticleId><ArticleId IdType="pmc">8604724</ArticleId></ArticleIdList></Reference><Reference><Citation>Favresse J, Gillot C, Bayart J-L, et al. Vaccine-induced binding and neutralizing antibodies against Omicron 6 months after a homologous BNT162b2 booster. J Med Virol. 2023;95:e28164.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.28164</ArticleId><ArticleId IdType="pubmed">36131356</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>